Descripción de la empresa
ADC Therapeutics SA operates within the healthcare sector, specifically functioning in the biotechnology industry by providing an antibody drug conjugate (ADC) technology platform across Switzerland and the United States. The firm's core business revolves around developing and commercializing its flagship product, ZYNLONTA, which is a CD19-directed ADC that has secured accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission. As of the latest reporting period, the company maintains a market capitalization of $472.60M and employs a workforce of 188 individuals to support its research and development and commercialization efforts. With an annual revenue of $81.36M, ADC Therapeutics SA presents a mid-cap profile that suggests a specialized position in the oncology space, where revenue figures are heavily influenced by the uptake of its single flagship asset rather than a diversified product portfolio.
Salud financiera
The company reported total revenue of $81.36M over the trailing twelve months, yet this figure masks a significant operational deficit reflected in a net income of $-142,623,008 and an EBITDA of $-105,390,000. The substantial gap between the positive revenue and the deeply negative net income reveals a cost structure where expenses, likely driven by high clinical trial costs, R&D expenditures, and commercialization overheads, far exceed current sales generation. This dynamic results in a free cash flow of $-103,812,000, indicating that the company is currently burning cash and lacks immediate financial flexibility to fund operations without external capital injections. The margin profile further underscores these challenges, with a gross margin of -32.2%, an operating margin of -69.3%, and a profit margin of -175.3%, all signaling that the business model is not yet profitable at the current scale of operations. On the balance sheet, the company holds $261.34M in cash against total debt of $439.55M, while the debt-to-equity ratio is listed as N/A due to the lack of positive equity metrics. Despite the negative equity position, the current ratio stands at 4.37, which indicates a strong ability to meet short-term liabilities with its liquid assets, providing a buffer against immediate liquidity crises. Furthermore, the return on equity is N/A and the return on assets is -20.6%, metrics that collectively reveal that management has not yet generated returns on invested capital, a common characteristic for biotechnology firms in the pre-profitability phase.
Evaluación de valoración
Valuation multiples for ADC Therapeutics SA reflect its status as a pre-revenue or early-stage profitable entity, evidenced by a P/E ratio (TTM) of N/A and a forward P/E of -2.50. The divergence between these metrics, particularly the negative forward P/E, implies that the market expects the company to remain unprofitable for the foreseeable future or anticipates a significant restructuring of its earnings trajectory before positive earnings can be realized. The price-to-book ratio is recorded at -2.52, which indicates that the stock trades at a negative premium relative to its book value, a situation typical for companies with intangible-heavy assets and substantial accumulated losses. Alternative valuation metrics such as the price-to-sales ratio of 5.81 and an EV/EBITDA of -6.17 suggest that investors are pricing the company based on future revenue potential and pipeline value rather than current earnings power. In terms of trading range, the stock has a 52-week high of $4.98 and a 52-week low of $1.05, meaning the current price sits significantly below the 52-week high, reflecting market volatility and sentiment shifts within the biotech sector. The beta value of 1.95 highlights that the stock exhibits high price volatility relative to the broader market, moving with a magnitude nearly twice as large as the general index, which increases both the risk and the potential for rapid capital appreciation or depreciation.
Growth & Income
ADC Therapeutics SA demonstrated a robust revenue growth rate of 36.4% year-over-year, while earnings growth is listed as N/A due to the company's continued losses. Since earnings are not growing at a positive rate, the expansion in revenue is being outpaced by the acceleration of costs or expenses, implying that the company is in an investment-heavy phase to secure regulatory approvals and market penetration. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is being reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms seeking to build a pipeline, though it necessitates continuous access to capital markets or cash reserves to sustain operations. Overall, the growth and income profile is characterized by high revenue expansion coupled with a complete absence of current profitability or shareholder distributions, positioning the company as a pure-play growth vehicle dependent on future product milestones.